- Home
- DXR vs IGC Comparison
DXR vs IGC Comparison
Compare DXR & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- IGC
- Stock Information
- Founded
- DXR 1970
- IGC 2005
- Country
- DXR United States
- IGC United States
- Employees
- DXR N/A
- IGC N/A
- Industry
- DXR Medical/Dental Instruments
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- IGC Health Care
- Exchange
- DXR Nasdaq
- IGC Nasdaq
- Market Cap
- DXR 46.9M
- IGC 39.8M
- IPO Year
- DXR N/A
- IGC N/A
- Fundamental
- Price
- DXR $13.00
- IGC $0.40
- Analyst Decision
- DXR Strong Buy
- IGC Strong Buy
- Analyst Count
- DXR 1
- IGC 2
- Target Price
- DXR $25.00
- IGC $4.00
- AVG Volume (30 Days)
- DXR 6.1K
- IGC 747.7K
- Earning Date
- DXR 01-01-0001
- IGC 11-11-2025
- Dividend Yield
- DXR N/A
- IGC N/A
- EPS Growth
- DXR 3.46
- IGC N/A
- EPS
- DXR 0.36
- IGC N/A
- Revenue
- DXR $66,306.00
- IGC $1,327,000.00
- Revenue This Year
- DXR N/A
- IGC $3.54
- Revenue Next Year
- DXR N/A
- IGC $15.12
- P/E Ratio
- DXR $35.22
- IGC N/A
- Revenue Growth
- DXR N/A
- IGC 24.95
- 52 Week Low
- DXR $6.55
- IGC $0.25
- 52 Week High
- DXR $14.00
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- DXR 57.62
- IGC 48.15
- Support Level
- DXR $12.70
- IGC $0.38
- Resistance Level
- DXR $14.00
- IGC $0.44
- Average True Range (ATR)
- DXR 0.52
- IGC 0.02
- MACD
- DXR -0.13
- IGC -0.00
- Stochastic Oscillator
- DXR 50.00
- IGC 35.50
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.